company background image
A214390 logo

Kyongbo Pharmaceutical KOSE:A214390 Stock Report

Last Price

₩7.44k

Market Cap

₩177.9b

7D

0%

1Y

12.6%

Updated

30 Apr, 2024

Data

Company Financials

Kyongbo Pharmaceutical Co., Ltd

KOSE:A214390 Stock Report

Market Cap: ₩177.9b

A214390 Stock Overview

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally.

A214390 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance4/6
Financial Health2/6
Dividends0/6

Kyongbo Pharmaceutical Co., Ltd Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kyongbo Pharmaceutical
Historical stock prices
Current Share Price₩7,440.00
52 Week High₩10,950.00
52 Week Low₩6,060.00
Beta1.14
1 Month Change0%
3 Month Change1.78%
1 Year Change12.56%
3 Year Change-41.65%
5 Year Change-26.70%
Change since IPO-78.28%

Recent News & Updates

Recent updates

Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet

Mar 09
Kyongbo Pharmaceutical (KRX:214390) Has A Somewhat Strained Balance Sheet

What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?

Feb 02
What Type Of Shareholders Own The Most Number of Kyongbo Pharmaceutical Co., Ltd (KRX:214390) Shares?

Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Jan 12
Kyongbo Pharmaceutical Co., Ltd's (KRX:214390) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock?

Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?

Dec 25
Did You Miss Kyongbo Pharmaceutical's (KRX:214390) Impressive 107% Share Price Gain?

Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?

Dec 08
Is Kyongbo Pharmaceutical (KRX:214390) A Risky Investment?

Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?

Nov 18
Does Kyongbo Pharmaceutical's (KRX:214390) Statutory Profit Adequately Reflect Its Underlying Profit?

Shareholder Returns

A214390KR PharmaceuticalsKR Market
7D0%2.1%2.2%
1Y12.6%8.6%6.7%

Return vs Industry: A214390 exceeded the KR Pharmaceuticals industry which returned 8.6% over the past year.

Return vs Market: A214390 exceeded the KR Market which returned 6.7% over the past year.

Price Volatility

Is A214390's price volatile compared to industry and market?
A214390 volatility
A214390 Average Weekly Movement6.8%
Pharmaceuticals Industry Average Movement4.5%
Market Average Movement5.2%
10% most volatile stocks in KR Market11.7%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A214390 has not had significant price volatility in the past 3 months.

Volatility Over Time: A214390's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1987n/an/awww.kbpharma.co.kr

Kyongbo Pharmaceutical Co., Ltd manufactures and sells active pharmaceutical ingredients and finished drugs in South Korea and internationally. The company offers general, cephalosporins, and anti-cancer APIs; prescription drugs, including anesthetic, cardiovascular, digestive, and antibiotics; and OTC drugs. It also provides medical devices, including portable X-ray machine and ultrasonic diagnostic equipment; and extraporeal shockwave therapy and temperature control PROBE.

Kyongbo Pharmaceutical Co., Ltd Fundamentals Summary

How do Kyongbo Pharmaceutical's earnings and revenue compare to its market cap?
A214390 fundamental statistics
Market cap₩177.87b
Earnings (TTM)₩2.97b
Revenue (TTM)₩216.36b

59.8x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A214390 income statement (TTM)
Revenue₩216.36b
Cost of Revenue₩153.78b
Gross Profit₩62.58b
Other Expenses₩59.60b
Earnings₩2.97b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)124.42
Gross Margin28.92%
Net Profit Margin1.37%
Debt/Equity Ratio50.7%

How did A214390 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.